<?xml version='1.0' encoding='utf-8'?>
<document id="28940404"><sentence text="A rapid and simple HPTLC assay for therapeutic drug monitoring of capecitabine in colorectal cancer patients."><entity charOffset="66-78" id="DDI-PubMed.28940404.s1.e0" text="capecitabine" /></sentence><sentence text="Capecitabine is a prodrug of 5-flurouracil, employed as a broad spectrum chemotherapeutic agent"><entity charOffset="0-12" id="DDI-PubMed.28940404.s2.e0" text="Capecitabine" /><entity charOffset="29-42" id="DDI-PubMed.28940404.s2.e1" text="5-flurouracil" /><pair ddi="false" e1="DDI-PubMed.28940404.s2.e0" e2="DDI-PubMed.28940404.s2.e0" /><pair ddi="false" e1="DDI-PubMed.28940404.s2.e0" e2="DDI-PubMed.28940404.s2.e1" /></sentence><sentence text=" It is also used as monotherapy or a combination chemotherapy agent for the treatment of colorectal cancer" /><sentence text=" Capecitabine is administered in combination with oxaliplatin and hence it is essential to determine that co-administration does not affect its metabolism"><entity charOffset="1-13" id="DDI-PubMed.28940404.s4.e0" text="Capecitabine" /><entity charOffset="50-61" id="DDI-PubMed.28940404.s4.e1" text="oxaliplatin" /><pair ddi="false" e1="DDI-PubMed.28940404.s4.e0" e2="DDI-PubMed.28940404.s4.e0" /><pair ddi="false" e1="DDI-PubMed.28940404.s4.e0" e2="DDI-PubMed.28940404.s4.e1" /></sentence><sentence text=" To determine the plasma concentration of capecitabine a simple HPTLC method was developed and validated"><entity charOffset="42-54" id="DDI-PubMed.28940404.s5.e0" text="capecitabine" /></sentence><sentence text=" Blood samples from 12 patients with colorectal cancer were collected and analyzed by the HPTLC method with a reference internal standard" /><sentence text=" Out of these 12 patients, six were treated with capecitabine monotherapy and another six were treated with capecitabine + oxaliplatin combination therapy"><entity charOffset="49-61" id="DDI-PubMed.28940404.s7.e0" text="capecitabine" /><entity charOffset="108-134" id="DDI-PubMed.28940404.s7.e1" text="capecitabine + oxaliplatin" /><pair ddi="false" e1="DDI-PubMed.28940404.s7.e0" e2="DDI-PubMed.28940404.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28940404.s7.e0" e2="DDI-PubMed.28940404.s7.e1" /></sentence><sentence text=" The results of analysis indicated that there was no significant drug-drug interaction and the co-administration of oxaliplatin did not affect the metabolism of capecitabine"><entity charOffset="116-127" id="DDI-PubMed.28940404.s8.e0" text="oxaliplatin" /><entity charOffset="161-173" id="DDI-PubMed.28940404.s8.e1" text="capecitabine" /><pair ddi="false" e1="DDI-PubMed.28940404.s8.e0" e2="DDI-PubMed.28940404.s8.e0" /><pair ddi="false" e1="DDI-PubMed.28940404.s8.e0" e2="DDI-PubMed.28940404.s8.e1" /></sentence><sentence text=" This method is sensitive, robust and specific and allows analysis of multiple samples simultaneously, making it suitable for therapeutic drug monitoring of capecitabine"><entity charOffset="157-169" id="DDI-PubMed.28940404.s9.e0" text="capecitabine" /></sentence><sentence text="" /></document>